Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: A screening strategy in the perspective of rural India

European Journal of Cancer Prevention

Volumn 11, Issue 5, 2002, Pages 447-456

  Duttagupta, C ^a   Sengupta, S ^a   Roy, M ^a   Sengupta, D ^a   Chakraborty, S ^a   Bhattacharya, P ^a   Roy, S ^a   Ghosh, S ^a  

^a INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

Cervical cancer screening strategy; Cervical erosion; HPV16 18 infection

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; FEMALE; GYNECOLOGIC CANCER; HUMAN; INDIA; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ACETIC ACID; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; INDICATORS AND REAGENTS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RURAL HEALTH; SEVERITY OF ILLNESS INDEX; STATISTICS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; WOMEN'S HEALTH;

EID: 0036805846     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200210000-00007     Document Type: Article

References (23)

1. Bethesda Workshop (1992). The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses: Report of the 1991 Bethesda workshop. J Rep Med 37: 383-6.
2. Bosch FX, Rohan T, Schneider A, et al. (2001). Papillomavirus research update: Highlights of the Barcelona HPV 2000 International Papillomavirus Conference. J Clin Pathol 54: 163-75.
3. Digene Technical News Bulletin (2001). Czech Republic adopts HPV testing for primary cancer screening. Marks First European Country to Enact HPV Legislation Act No. 183/ 2000 Sb. Technical News Bulletin Ins/hpv/002, Jan 2001.
4. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC, et al. (2001). Policy analysis of cervical cancer screening strategies in low- resource settings. Clinical benefits and cost-effectiveness. JAMA 285: 3107-15.
5. Haraf DJ, Nodzensky E, Brachman D, et al. (1996). Clin Cancer Res 2: 755-62.
6. Herrero R, Hildesheim A, Bratti C, et al. (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-74.
7. Human Development Report (1997). Table 28. Women & Capabilities. UNDP.
8. IARC (1986). International Agency for Research on Cancer Working Group on Evaluation of Cervical Cancer Screening Programs. Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implications for screening policies. Lancet 293: 659-64.
9. IARC (1995). International Agency for Research on Cancer Working Group. Human Papillomaviruses; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans No. 64. IARC, Lyon, pp. 35-282.
10. Kitchener HC, Symonds P (1999). Detection of cervical intra-epithelial neoplasia in developing countries. Lancet 353: 856-7.
11. Kjaer SK, van den Brule AJ, Bock JE, et al. (1997). Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: Are there different risk profiles for oncogenic and non oncogenic HPV types. Cancer Epidemiol Biomarkers Prev 6: 799-805.
12. Manos MM, Wright DK, Lewis AJD, Broker TR, Wolinsky SM (1989). The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Molecular Diagnostics of Human Cancer. (eds Furth M and Greaves MF); Cold Spring Harbor Press, New York, pp. 209-14.
13. Murthy NS, Agarwal SS, Prabhakar AK, Sharma S, Das DK (1993). Estimation of reduction of lifetime risk of cervical cancer through one lifetime screening. Neoplasma 40: 255-8.
14. Sellors JW, Mahony JB, Kaczorowski J, et al. (2000). Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 163: 503-8.
15. Sengupta A, Duttagupta C, Bandyopadhyay S, et al. (2000). An exploratory statistical analysis of the effect of demographic risk factors on uterine cervical squamous intraepithelial lesion. Cal Stat Assoc Bull 50: 308-24.
16. Shankaranarayanan R, Shyamalakumari B, Wesley R, Sreedevi AN, Parkin DM, Nair MK (1999). Visual inspection with acetic acid in the early detection of cervical cancers and precursors. Int J Cancer 80: 161-3.
17. Singh V, Sehgal A, Luthra UK (1992). Screening of cervical cancer by direct inspection. BMJ 304: 534-5.
18. University of Zimbabwe/JHPIEGO Cervical Cancer Project (1999). Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 353: 869-73.
19. Wallboomers JM, Jacobs MV, Manos MM, et al. (1999). Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-9.
20. Wallin KL, Wiklund F, Augstrom T, et al. (1999). Type specific persistence of human papillomavirus DNA before the development of cervical cancer. New Engl J Med 341: 1633-8.
21. Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A (2000). HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283: 81-6.
22. Womack SD, Chirenje ZM, Blumenthal PD, et al. (2000). Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. Br J Obstet Gynaecol 107: 33-8.
23. Zielinski GD, Snijders PJF, Rozendaal L, et al. (2001). HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 85: 398-404.